Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Sabag also recently made the following trade(s):

• On Tuesday, March 17th, Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28.

Teva Pharmaceutical Industries Trading Up 1.5%

NYSE TEVA opened at $35.86 on Wednesday. The business’s 50-day moving average price is $31.19 and its two-hundred day moving average price is $29.57. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The firm has a market capitalization of $41.24 billion, a PE ratio of 26.97, a price-to-earnings-growth ratio of 3.42 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $25,000. Allworth Financial LP raised its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the period. Grove Bank & Trust raised its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the period. EverSource Wealth Advisors LLC raised its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the period. Finally, Global Retirement Partners LLC raised its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts are lifting Teva’s fair value and reframing the investment case (higher fair value to $40.09), signaling improved Street confidence in R&D, biosimilars and capital allocation — a clear near?term catalyst for demand. Read More.
• Positive Sentiment: Multiple brokerages have raised price targets recently (reports include increases up to $45), and Piper Sandler reiterated an Overweight — these upgrades and higher targets support buying interest and headline momentum. Read More.
• Positive Sentiment: Teva will present at the BofA Securities Health Care Conference on May 12 (EVP of R&D to speak). Management comments on pipeline, R&D progress or commercial execution there could produce a directional move. Read More.
• Neutral Sentiment: Street estimates remain constructive but not unanimous — consensus near?term EPS estimates sit around ~$2.5–2.6 for the year, which frames valuation (current P/E in the mid?20s). This keeps upside tied to execution and guidance.
• Negative Sentiment: Insider selling: EVP Christine Fox sold 21,258 shares (~25% reduction of her stake) at an average price ~$35.31; such insider dispositions can be read as a negative signal or simply routine liquidity. Read More.
• Negative Sentiment: Large insider sale: Director/executive Mark Sabag sold 144,180 shares (~64% reduction) at ~ $34.99 — a sizable disposition that may temper sentiment from analyst upgrades. Read More.

Wall Street Analyst Weigh In

A number of research firms have commented on TEVA. Barclays upped their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Scotiabank boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.56.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.